Compound News and Research

RSS

Omeros announces positive results from OMS824 Phase 1 clinical program

Omeros Corporation today announced positive results from its Phase 1 clinical program evaluating OMS824, the lead compound from its phosphodiesterase 10 (PDE10) program.

31 May 2013

Discovery opens doors to new therapies for sepsis

Despite numerous advances in treating infections and disease, effective treatments for sepsis remain elusive. A new discovery published in the June 2013 issue of The FASEB Journal not only could help health care providers predict who is more and less likely to develop sepsis, but it also opens the doors to new therapies that actually address the root cause of the problem, rather than just managing the symptoms.

31 May 2013

Oncothyreon, Array BioPharma to develop and commercialize ARRY-380 for breast cancer patients

Oncothyreon Inc. and Array BioPharma Inc. today announced that they will collaborate to develop and commercialize ARRY-380, an orally active, reversible and selective small-molecule HER2 inhibitor.

30 May 2013

Ruthenium complexes could pave way for cancer treatments, say UT Arlington researchers

A team of UT Arlington researchers has identified two ruthenium-based complexes they believe could pave the way for treatments that control cancer cell growth more effectively and are less toxic for patients than current chemotherapies.

30 May 2013

Targacept initiates TC-5214 Phase 2b clinical study in patients with OAB

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics, today announced the initiation of a Phase 2b clinical study of TC-5214 as a treatment for overactive bladder.

29 May 2013

Transplantation of human stem cells improves muscle function in rats used to model ALS

Transplantation of human stem cells in an experiment conducted at the University of Wisconsin-Madison improved survival and muscle function in rats used to model ALS, a nerve disease that destroys nerve control of muscles, causing death by respiratory failure.

29 May 2013

Bay Pines VA Healthcare System to study effectiveness of 7-Keto compound in PTSD

The Bay Pines VA Healthcare System announced that it will begin a research study related to post-traumatic stress disorder. The study will focus on whether the use of a naturally occurring compound known as 7-Keto assists in the treatment of PTSD.

29 May 2013

New approach to battle prostate cancer

Dr. Jung-Mo Ahn, associate professor of chemistry at The University of Texas at Dallas, has designed and synthesized a novel small molecule that might become a large weapon in the fight against prostate cancer.

29 May 2013

Exposure to bug or weed killers is associated with higher risk of Parkinson's disease

A large analysis of more than 100 studies from around the world shows that exposure to pesticides, or bug and weed killers, and solvents is likely associated with a higher risk of developing Parkinson's disease. The research appears in the May 28, 2013, print issue of Neurology-, the medical journal of the American Academy of Neurology.

28 May 2013

Synthetic compound derived from sea anemone toxin shows potential to treat obesity

Scientists at UC Irvine reported this week that a synthetic compound ShK-186, originally derived from a sea anemone toxin, has been found to enhance metabolic activity and shows potential as a treatment for obesity and insulin resistance.

28 May 2013

Tomatoes made more tasty and longer-lasting with purple GM varieties

Tomatoes, said to be the world's most popular fruit, can be made both better-tasting and longer-lasting thanks to UK research with purple GM varieties.

24 May 2013

Potential new treatment approaches for liver diseases

By discovering the new mechanism by which estrogen suppresses lipid synthesis in the liver, UC Irvine endocrinologists have revealed a potential new approach toward treating certain liver diseases.

24 May 2013

Senate immigration bill would ease restrictions on foreign health workers; Measure advances to increase scrutiny on compounding pharmacies

On Capitol Hill, several legislative efforts are moving forward on health issues. Among them is an effort by the Massachusetts delegation to keep bonus Medicare payments for the state's hospitals, while House Republicans are looking for another way to deal with a bill to fund high-risk insurance pools.

24 May 2013

Cinnamon compounds show some promise in the effort to fight Alzheimer's disease

Cinnamon: Can the red-brown spice with the unmistakable fragrance and variety of uses offer an important benefit? The common baking spice might hold the key to delaying the onset of -- or warding off -- the effects of Alzheimer's disease.

24 May 2013

Spring Bank Pharmaceuticals starts Phase I study of SB 9200 for treatment of HCV infection

Spring Bank Pharmaceuticals, Inc., a biopharmaceutical company developing innovative medicines for the treatment of viral infections, today announced that it has initiated dosing in a Phase I study of SB 9200, its investigational, once daily, oral therapy for the treatment of HCV infection.

24 May 2013

Groundbreaking anti-aging dietary supplement

Jeunesse Global, a network marketing company that dedicates its research to promoting healthy and youthful living, has produced the solution to one of the fundamental causes of cellular aging.

23 May 2013

Physicists develop novel technique that can detect molecular variants

Harvard physicists have developed a novel technique that can detect molecular variants in chemical mixtures - greatly simplifying a process that is one of the most important, though time-consuming, processes in analytical chemistry.

23 May 2013

Research findings reveal promising new anti-addiction drug

Researchers at Johns Hopkins have unraveled the molecular foundations of cocaine's effects on the brain, and identified a compound that blocks cravings for the drug in cocaine-addicted mice.

23 May 2013

Pfizer halts Phase 3 open-label, two-arm study of lymphoma drug

Pfizer Inc. announced today the discontinuation of a Phase 3 randomized, open-label, two-arm study (B1931008) evaluating the safety and efficacy of the investigational compound inotuzumab ozogamicin in patients with relapsed or refractory CD22+ aggressive non-Hodgkin lymphoma who are not candidates for intensive high-dose chemotherapy.

From Pfizer, Inc. 21 May 2013

AbbVie starts Phase 3 clinical study of atrasentan in patients with diabetic nephropathy

AbbVie announced today the initiation of a Phase 3 clinical study called SONAR (Study Of Diabetic Nephropathy with Atrasentan) to assess the effects of the investigational compound atrasentan - when added to standard of care - on progression of kidney disease in patients with stage 2 to 4 chronic kidney disease and type 2 diabetes.

21 May 2013

Compound News and Research

Omeros announces positive results from OMS824 Phase 1 clinical program

Discovery opens doors to new therapies for sepsis

Oncothyreon, Array BioPharma to develop and commercialize ARRY-380 for breast cancer patients

Ruthenium complexes could pave way for cancer treatments, say UT Arlington researchers

Targacept initiates TC-5214 Phase 2b clinical study in patients with OAB

Transplantation of human stem cells improves muscle function in rats used to model ALS

Bay Pines VA Healthcare System to study effectiveness of 7-Keto compound in PTSD

New approach to battle prostate cancer

Exposure to bug or weed killers is associated with higher risk of Parkinson's disease

Synthetic compound derived from sea anemone toxin shows potential to treat obesity

Tomatoes made more tasty and longer-lasting with purple GM varieties

Potential new treatment approaches for liver diseases

Senate immigration bill would ease restrictions on foreign health workers; Measure advances to increase scrutiny on compounding pharmacies

Cinnamon compounds show some promise in the effort to fight Alzheimer's disease

Spring Bank Pharmaceuticals starts Phase I study of SB 9200 for treatment of HCV infection

Groundbreaking anti-aging dietary supplement

Physicists develop novel technique that can detect molecular variants

Research findings reveal promising new anti-addiction drug

Pfizer halts Phase 3 open-label, two-arm study of lymphoma drug

AbbVie starts Phase 3 clinical study of atrasentan in patients with diabetic nephropathy

Advancing therapeutic biopolymer development eBook

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Latest News